加载中
NASDAQHealthcareMedical - Devices
最新数据
US$0.5806
−US$0.0168 · -2.81%
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
常规交易时段
US$0.5806
−US$0.0168 · -2.81%
盘中时间采用ET。市场数据可能有所延迟。
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
日内区间
当前US$0.5806
52周区间
当前US$0.5806
盘中时间采用ET。市场数据可能有所延迟。
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
日内区间
当前US$0.5806
52周区间
当前US$0.5806
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 470.6万 USD | 434.6万 USD | 242.8万 USD | 37.7万 USD | 50万 USD |
| 销货成本 | 754.2万 USD | 826.6万 USD | 847.8万 USD | 361.4万 USD | 58.5万 USD |
| 毛利 | −283.6万 USD | −392万 USD | −605万 USD | −323.7万 USD | −8.5万 USD |
| 研究与开发 | 56.78亿 USD | 599.2万 USD | 725.2万 USD | 1146.6万 USD | 929.6万 USD |
| 销售、一般及管理费用 | 415.77亿 USD | 366.19亿 USD | 3565.8万 USD | 3981.9万 USD | 1803.8万 USD |
| 营业费用 | 4680.4万 USD | 4213.2万 USD | 4243.2万 USD | 5293.4万 USD | 2733.4万 USD |
| 利息收入 | 38.6万 USD | 32.2万 USD | 42.4万 USD | 8.8万 USD | — |
| 利息支出 | 2.2万 USD | 2.6万 USD | 41.6万 USD | 8000 USD | 65.9万 USD |
| 折旧和摊销 | 87.2万 USD | 116.7万 USD | 249.9万 USD | 193.6万 USD | 4000 USD |
| 营业利润 | −4964万 USD | −4605.2万 USD | −4848.2万 USD | −5617.1万 USD | −2741.9万 USD |
| 净利润 | −5801万 USD | −4552.9万 USD | −5266.6万 USD | −5617.1万 USD | −2807.8万 USD |
公司数据更新于 2026年10月13日。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$2.00
上涨空间 244.47%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI444.97万0.00%2.3万亿 USD0.03%US$380.83-0.19%
iShares Russell 2000 ETFIWM212.12万0.00%787.4亿 USD0.19%US$276.33-0.57%
Vanguard Extended Market ETFVXF182.16万0.00%954亿 USD0.05%US$231.9-0.70%
Vanguard Russell 2000 ETFVTWO83.37万0.00%180亿 USD0.06%US$111.6-0.60%
iShares Russell 2000 Growth ETFIWO83.1万0.01%139.17亿 USD0.24%US$350.73-0.84%
iShares Micro-Cap ETFIWC29.02万0.02%13.17亿 USD0.60%US$179.65-1.11%
Vanguard Russell 2000 Growth ETFVTWG15.84万0.01%17亿 USD0.06%US$255.96-0.90%
iShares Russell 2500 ETFSMMD4.6万0.00%40.62亿 USD0.23%US$85.64-0.43%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGiShares Russell 2500 ETFSMMDAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
